Date: 2016-08-12
Type of information: Private placement
Company: Arrowhead Pharmaceuticals (USA - CA)
Investors: Orbimed (USa - NY) RA Capital Management (USA - MA) Perceptive Advisors (USA - NY) RTW Investments (USA - NY) other institutional investors
Amount: $45 million
Funding type: private placement
Planned used: Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
Others: * On August 12, 2016, Arrowhead Pharmaceuticals announced that it closed a private offering with a select group of investors including Orbimed, RA Capital Management , Perceptive Advisors , RTW Investments and certain other institutional investors. Gross proceeds were $45 million . Approximately 7.63 million shares of common stock were issued at a price of $5.90 per share. Cantor Fitzgerald & Co. acted as sole placement agent for the private offering. Trout Capital LLC and Chardan Capital Markets LLC acted as financial advisors. * On August 9, 2016, Arrowhead Pharmaceuticals announced that it has priced a private offering of its common stock with gross proceeds expected to be $45 million . The offering was priced at $5.90 per share. Cantor Fitzgerald & Co. acted as sole placement agent for the offering.
Approximately 7.63 million shares of common stock are expected to be issued at the closing of the offering. The offering is expected to close on or about August 12, 2016 , subject to the satisfaction of customary closing conditions.
Therapeutic area:
